Drug manufacturer Eagle Pharmaceuticals has declared the availability of its proxy materials and audited financial reports for the 2023 and 2024 financial years.
Eagle Pharmaceuticals, Inc., a fully integrated pharmaceutical company specializing in research and development, clinical, manufacturing, and commercial activities, has announced the availability of proxy materials for its 2025 Annual Meeting of Stockholders.
The company, which is committed to developing innovative medicines that improve patients' lives and aims to address underserved therapeutic areas and contribute to personalized medicine in cancer care, has scheduled its annual meeting for October 17, 2025. The meeting will be held virtually at 10:00 a.m. Eastern Time.
The proxy materials, which contain important information about the meeting and the company's business, are available online at www.proxyvote.com and https://investor.eagleus.com/events-presentations. The Company is delivering a Notice of Internet Availability of Proxy Materials to stockholders of record as of the close of business on August 18, 2025.
Eagle Pharmaceuticals, Inc.'s portfolio includes a range of commercialized products such as PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), BYFAVO®, and BARHEMSYS®.
For investor relations inquiries, please contact Lisa M. Wilson at T: 212-452-2793 or E: [email protected].
Additional information about Eagle Pharmaceuticals, Inc. can be found on its website at www.eagleus.com. The company's audited financial statements as of and for the years ended December 31, 2024 and 2023, are available at https://investor.eagleus.com/events-presentations.
The person representing the shareholders at the 2025 annual meeting on October 17, 2025, virtually, is not publicly specified.
Eagle Pharmaceuticals, Inc. is a publicly traded company with the ticker symbol EGRX on the OTC Markets. The company's oncology and CNS/metabolic critical care pipeline includes product candidates for multiple disease states.
Read also:
- Planned construction of enclosures within Görlitzer Park faces delays
- Foreign financial aid for German citizens residing abroad persists
- United States and Russia prepared to delve deeper into negotiations regarding the Sakhalin 1 oil and gas project
- Heavy-duty zero-emission vehicles may be exempted from tolls for how long, according to the commission's proposal.
